Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: A new model for preclinical studies in giant-cell arteritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 3, 2014, Pages 616-623

  Corbera Bellalta, Marc ^a   García Martínez, Ana ^a,b   Lozano, Ester ^a   Planas Rigol, Ester ^a   Tavera Bahillo, Itziar ^a   Alba, Marco A ^a   Prieto González, Sergio ^a   Butjosa, Montserrat ^a   Espígol Frigolé, Georgina ^a   Hernández Rodríguez, José ^a   Fernández, Pedro L ^a   Roux Lombard, Pascale ^c   Dayer, Jean Michel ^d   Rahman, Mahboob U ^e,f   Cid, Maria C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINES; CORTICOSTEROIDS; CYTOKINES; GIANT CELL ARTERITIS; SYSTEMIC VASCULITIS;

BIOLOGICAL MARKERS; COLLAGEN; CYTOKINES; DEXAMETHASONE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; LAMININ; MODELS, BIOLOGICAL; PROTEOGLYCANS; RNA, MESSENGER; TEMPORAL ARTERIES; TISSUE CULTURE TECHNIQUES;

EID: 84893816416     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202883     Document Type: Article

References (28)

1. Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012;8:509-21.
2. Cid MC, García-Martínez A, Lozano E, et al. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007;33:819-34. (Pubitemid 350130315)
3. García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008;59:422-30. (Pubitemid 351399213)
4. Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine 2011;90:186-93.
5. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30. (Pubitemid 351650517)
6. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8. (Pubitemid 37296477)
7. Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93. (Pubitemid 19181011)
8. Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199:173-83. (Pubitemid 38129698)
9. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-15.
10. Weyand CM, Tetzlaff N, Björnsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;40:19-26. (Pubitemid 27044032)
11. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34. (Pubitemid 36605224)
12. Cid MC, Hoffman MP, Hernández- Rodríguez J, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistente of disease activity in giant-cell arteritis. Rheumatology 2006;45:1356-63. (Pubitemid 44605469)
13. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004;43:294-301. (Pubitemid 38313176)
14. Visvanathan S, Rahman MU, Hoffman GS, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology 2011;50:2061-70.
15. García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 2010;62:835-41.
16. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51:151-6.
17. Brack A, Geisler A, Martinez-Taboada VM, et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997;3:530-43. (Pubitemid 127499166)
18. Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997;99:2842-50. (Pubitemid 27278659)
19. Piggott K, Deng J, Warrington K, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 2011;123:309-18.
20. Benton G, George J, Kleinman HK, et al. Advancing science and technology via 3D culture on basement membrane matrix. J Cell Physiol 2009;221:18-25.
21. Lozano E, Segarra M, García-Martínez A, et al. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 2008;67:1581-8.
22. Segarra M, García-Martínez A, Sánchez M, et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007;66:1429-35. (Pubitemid 350032648)
23. Tetlow LC, Harper N, Dunningham T, et al. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998;57:25-32. (Pubitemid 28175216)
24. Blain H, Abdelmouttaleb I, Belmin J, et al. Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures. J Gerontol A Biol Sci Med Sci 2002;57:M241-5. (Pubitemid 34263302)
25. Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993;361:79-82. (Pubitemid 23020778)
26. García-Martínez A, Lozano E, Segarra M, et al. Human temporal artery culture on Matrigel: a useful method for preclinical assessment of functional changes after intervention. Arthritis Rheum 2007;56:S497.
27. Corbera-Bellalta M, Lozano E, García-Martínez A, et al. Changes in inflammatory-mediators induced by glucocorticoids in cultured human temporal arteries from patients with giant-cell arteritis. Arthritis Rheum 2008;58:S929.
28. Molloy D, Connolly M, McCormick J, et al. Acute serum amyloid A and TLR2 activation induces pro-inflammatory mechanisms in a novel ex vivo temporal artery explant culture/model of giant cell arteritis. Ann Rheum Dis 2012;71 (Suppl 3):225.